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Genotoxic and epigenetic 
chemical carcinogenesis: one 
process, different mechanisms 
W. K. Lutz and P. Maier 
Chemieals that induce cancer in an intact organism are called carcinogens. This 
term does not differentiale between their vaTiaus modes of action. In this reliiew, 
Wemer Lutz and Peter Maier make a mechanistic distinction between 
carcinogens that alter the genetic information and carcinogens that interfere 
with epigenetic processes. They considercardnogenesis tobe an ongoing, part1y 
unavoidable process which is based on a succession of mutations, most likely in 
stem cells, leading to autonomaus cellular growth regulation. Chemical 
carcinogens either induce such changes through mutations (genotoxic carcino-
gens) or they aceeierate the accumulation of critica1 spontaneaus mut11tions 
(epigenetic carcinogens). Ex11mples are given for both classes of carcinogens, 
and for the processes that act at genoto:tic/nuclear 11nd epigenetic/mitotic Ievels. 
Cancer cells differ &om normal 
cells by their autonomaus and in· 
vasive growth in a tissue. This 
phenotype is a consequence of ir .. 
reversible, heritable changes in 
structure or expression of the gen .. 
etic material. Ouring the last few 
years, a number of genes have 
been identified in mammalian 
cells that seem to be involved in 
the process of neoplastic cell trans-
formation. These genes, which 
when active can confer on a cell fea .. 
tures of a canceraus phenotype, are 
termed proto-oncogenes. Many of 
these gene products are reJated to 
pathways that determine the ceU's 
response to growth-stimulating 
factors and/or differentiation, e.g. 
growth factors, growth factor 
receptors, cytoplasmic and nuclear 
rPgulatory proteins1• In normal 
cells, their expression is controlled 
by the specific requirements for 
growth and differentiation. 
Conversion of the proto-onco-
genes into oncogenes (activation) 
by genetic events, such as base-
pair substitution or translocations 
of the gene into actively tran-
scribed regions of the genome by 
chromosomal rearrangements2, are 
the best studied mechanisms. 
These mutations result in the ex-
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pression of abnormal gene prod-
uct, the deregulated expression of 
a proto-oncogene at the wrong 
time during ontogenesis of a cell, 
or the expression of an abundance 
of the proto-oncogene product. 
The mutations involved are char-
acteristic for the specific tissue and 
cause autonomaus clonal growth 
of tumour cells. 
Altematively, oncogene expres-
sion can be modified by the loss or 
inhibi tion of functions encoded by 
re;·;ulatory genes, the so-called 
tumour suppressor genes3• Sup-
pressor genes probably encode 
DNA-binding proteins that inhi-
bit the transcription of oncogenes 
or prevent the expression of the 
tumourigenic phenotype itself. 
This mechanism was proposed to 
play a role in familial predisposi-
tion to cancer (e.g. retinoblas-
toma)4. The cancer-causing gene 
can be present as a recessive trait 
and will be expressed when the 
other normal gene, which acts as a 
suppressor gene, is functioitally 
lost. This can occur in a clone of 
somatic ceUs as a result of a num· 
ber of chromosomal mechanisms, 
such as non-disjunction, mitotic 
recombination, !\ene conversion, 
or small deletions . A change in the 
genetically contr9lled pattem of 
cytosine methylation in the DNA 
is a further mechanism which 
might be responsible for perma-
nent oncogene expression. 
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CarcinogeneBis as a multi-stage 
process 
Some age-specific cancer ind-
dence rates rise exponentially with 
age. Analysisofthis time depen-
dence reveals that several distinct 
stages are involved in tumour 
growth (Fig. 1). The number of 
stages may be araund five to seven 
for most sites6, and it is likely that 
for some childhood cancer types 
( e.g.leukaemia, brain) the process 
begins in utero.ln vitro, at least two 
- oncogenes have to be expressed in 
order for a primary cell to be trans-
formed7. Different types of muta .. 
tions or a combination of them 
might be necessary at each stage of 
carcinogenesis. 
Initiation ofcarcinogenesis by 
chemical mutagens 
Chemieals that can interact with 
the genetic material and generate 
critical DNA lesions are called 
tumour initiating agents or geno· 
toxic carcinogens. Most of those 
identified so far cause gene muta-
tions, but this is probably due to 
the fact that this type of mutation is 
detectable efficiently by relatively 
sitnple microbial test systems. In 
fad, genotoxic chemieals often 
induce wide spectra of mutations. 
Evtdence exists that specific chem-
ical mutations can occur in codons 
of cellular proto .. oncogenes, as was 
shown with the c·Ha-rliS gene, 
using nitrosomethylurea8 or di .. 
methylbenzanthracene9• However, 
the appearance of specific aberrant 
chromosomes in tumourcells2 sug-
gests that induced chromosomal 
rearrangements and deletions 
have an equal or greater signifi~ 
cance as initial events. 
Directinterlldion with DNA 
The best studied interaction in-
volves covalent binding of the car-
cinogen to nuclear DNA10, either 
spontaneously (alkylating agents 
such as epoxides, mustards, alkyl 
sulphonates or alkyl halides) or 
after enzymaiic activation to an 
electrophilic metabolit~. This is 
the mechanism of most weil 
known potent chemical carclno-
gens, e.g. the polycydic aromatic 
hydrocarbons (benzo[a ]pyrene), 
aromatic amines (2-naphthyl-
amine), N-nitroso compounds (N-
riitrosodimethylam.ine), and com-
pounds containing an olefin with 
substituents that render it electro-
philic as in aflatoxins orvinylchlor· 
ide. If the resulting DNA adduct is 
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not removed and the lesion cor-
rectly repaired, gene mutations 
and, in rare cases, chromosome 
aberrations can arise following 
DNA replication. Mutations in-
duced in the mitochondrial DNA, 
especially in combination with 
mutaöons in the nucleus, might 
also play a role in carcinogenesis 11• 
Alteration ofchromosome 
structure 
Besides covalent DNA binding 
of the compound or one of its 
metabolites, DNA lesions can be 
induced by free radicals, as in the 
case of radiation. The resulting 
mutation wiH predominantly be 
due to chromosome breakage (re-
arrangements, deletions). One 
hypothesis is that some carcino-
gens exert their effect by generat-
ing reactive oxygen species (in-
cluding the hydroxyl radical) 
which in turn darnage DNA or 
DNA-protein complexes. This 
mechanism has been postulated 
for a number of ceßular peroxidant 
states12• 
The Iist of compounds includes 
those hepatic carcinogens that 
induce a proliferation of peroxi-
somes [phthalate plasticizers like 
di(2-ethylhexyl)phthalate or hypo-
lipidaemic agents such as clofi-
brate]. Although this is an appeal· 
ing hypothesis we are not aware of 
any report that demonstrates DNA 
darnage in a target tissue after 
treatment of animals with a peroxi-
some proliferator. 
lnterferencewithDNA replication 
The process of DNA replication 
can be disturbed, for example, by 
certain metal ions (such as Bel+, 
Cd2+, Ni2+) which can reduce tem-
plate fidelity, or by promoting the 
incorporation of mis-matching 
nucleotides, or by the disturbance 
of the nucleotide pool with base 
analogues and inhibitors of DNA-
precursor synthesis (e.g. ßuoro-
uracil, methothrexate). These 
interactions again predominantly 
result in structural chromosome 
aberrations13• 
lnterferencewithDNAsegregation 
Agents that induce numerical 
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chromosomal aberrations [e.g. 
spindie poisons like demecolcine 
(colcemid)] could also Iead to an 
enhanced expression of oncogene 
products. This can be achieved by 
increasing the copies of genes per 
cell (gene amplification, hyper-
ploidy) or by activation due 
to a hemizygotic gene constella-
tion involving suppressor- genes 
(hypoploidy). However, numerical 
chromosome aberrations often 
impair normal.cell growth and are 
unUkely to play an important role 
in the early steps of carcinogenesis. 
Interaction with DNA metabolism 
in damaged cells 
lt is important to realize that 
high doses of genotoxic agents 
induce local, often undetected, 
cytotoxicity in target tissue (necro-
sis). This might have happened in 
those experiments in whlch carci-
nogeniclty of chemieals was 
demonstrated. at highest exposure 
Ievels only. From in-vitro muta-
geniclty studies it is known that 
unphysiological conditions alone 
cause an increase in the number of 
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mutations14.1t cannot be ruled out 
that in vivo as weil, in heavily 
damaged but surviving and pro-
liferating cells, errors accumulate in 
pathways that are involved in the 
maintenance of an intact genome. 
Carcinogenesisasan ongoing, 
partlyunavoidableprocess 
Animals fed on a controUed diet 
free of known potent carcinogens 
also develop cancer. This back-
gmund rate of tumour incidence is 
called 'spontaneous' and indic~·-~~s 
that all requirements for cancer 
induction aTe met in the absence of 
added carcinogen. Carcinogenesis 
therefore must, to a degree, be 
considered an unavoidable pro-
cess. 
Spontaneaus DNA darnage 
results from intrinsic DNA insta-
bility, and from endogenaus elec-
trophiles and radicals. The first 
aspect includes spontaneaus 
deaminations of adenine and cyto-
sine and depurinations, as weil as 
base mispairings due to tautomer 
formation and the presence of 
mutagenic meta! ions. 
The Iist of endogenout:t elec-
trophiles includes S-adenosyl-
methionine, aldehydes {e.g. sugars, 
formaldehyde), epoxide inter-
mediates in the oxidation of aro-
matic amino acid derivatives and 
steroids, and quinones (e.g. from 
estrogens, c:atecholamines). The 
formation of radicals is also un-
avoidab]e because of the contin-
uaus leakage of the superoxide 
anion radical after the first reduc-
tion step of molecular oxygen by 
various cytochromes. Although 
protective enzyme systems (super-
oxide dismutase and peroxidases) 
have evolved for the protection of 
cellu1ar components, a minor frac-· 
tion will inevitably form the highly 
reactive hydroxyl radical ·OH in 
the presence of catalytic concentra-
tions of metal ions, especially iron. 
In addition to endogenaus 
sources ofDNA damage, there are 
also unavoidable environmental 
factors. The most important ones 
are probably ionizing · radiation 
arising from the decay of terrestrial 
radioactive material, including 
inhaled radon, and from cosmic 
rays, including ultraviolet light. 
It must therefore be concluded 
that a low Ievel of Dt~A darnage 
cannot be avoided. This conclusion 
is supported by the recent detec· 
tion of age-related DNA modifica-
tions in untreated rats 15 and the 
identification of activated proto-
oncogenes in spontaneaus hepato-
cellular tumours in mice16• In germ 
cells, these modifications may pl"Y 
an important roJe in evolutionary 
proc:esses. However, in somatic 
cells, they inevitably fonn the geno-
toxic basis for so-called spon-
tane'lus tumour formation. There-
fore, the introduction of the con· 
cep~ of an endogenaus basis for 
all steps required for Qrcinogen-
esis allows the hazard from ex-
posure to an exogenous chemical 
carcinogen to be estimated in 
terms of an increment only. 
Tumourpromotion 
The time in humans from the 
first critical mutation to the expres-
sion of a malignant tumour is be-
tween a few years (leukaemia from 
ionizing radiation) to more than 
two decades (lung cancer from 
smoking). This period is subject to 
modulation by endogenaus and 
exogenous, genetic and/or epigen-
etic factors. 
In studies on the role of inßam-
mation in cardnogenesis, it was 
found that certain compounds 
(phorbol esters in c:roton resin in 
the early experiments), when 
painted over a long period of time 
on the skin of mice, dramatic:ally 
increased skin tumour fonnation 
after a single administration of a 
genotoxic carc~ 'logen 17• The early 
effect of the genotoxic c:ompo:I~td 
was later termed initiation, while 
the long-term treatmentwas called 
tumour promotion. Treatment 
with the tumour promoter alone 
did not Iead to a significant 
increase in the number of tumours 
in these early experiments. Also, 
since the tumour promoters were 
not mutagenic in most short-term 
assays for mutagenicity, they were 
not classified as carc:inogens. 
However, latterly it has been 
discovered that tumour promoters 
alone can increase cancer inci-
dence if tested on large numbers of 
animals over their entire life span. 
It must be assumt!d that under 
these conditions the tumour prom· 
oter enhances the probability of 
the endogenaus and unavoidable 
DNA lesions being expressed as a 
tumour. 
Stimultltion of cell division 
Stimulation of target cell div-
ision for clonal expansion seems to 
be one common activity of tumour 
promoters 18• As c:arcinogenesis 
requires the accumulation of a cer-
tain number of genetic changes, it 
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is obvious that the rate of fixation 
of criticallesions in the genome 
can be ac:celerated by more rapid 
cell division. If the hypothesis that 
some DNA darnage is unavoidable 
is correct, tumour promoters will 
increase the tumour incidence in a 
bioassay by promoting sponta-
neously initiated cells19• 
An important distinction might 
be introduced at this point with 
respect to the different mechanis-
tic possibilities of inducing a mito-
genic respdnse: 
• Tumour promoters could ac:t 
direct1y as growth factors (estrone, 
diethylstilbestrol, perhaps TCDD)20, 
or interact with already modified 
growth fac:tor receptors. 
• They could stimulate ~wth 
factor production and release21 or 
affect growtb regulators further 
downstream (e.g. protein kinase C 
activation). 
• They could shift differentiated, 
resting cells ftom G0 to Gt cell·cyc:le 
phase (phenobarbita1)22• 
• They could induce restorative 
growth due to their cytotoxic activ-
ity (asbestos fibres, phenacetin, 
chloroform, genotoxic agents at 
high dose Ievels). 
• They could inhibit cellular dif-
ferentiation processes23 which 
usually ensure that maturing c:ells 
stop dividing. 
• They could interupt ce~ell 
communication, which seems to 
be necessary for stem cells to 
divide24• 
Endogenously induced 
proliferation ofinitiated cells 
U stimulation of cell division is 
of prime importance for tumour 
promotion, development and 
growth of the fertilized egg to the 
adult organism must be a critical 
period for tumour promotion. 
However, uncontrolled prolifera-
tion is not coJl\patiblewith organo-
genesis. In the adult, controlled 
stem cell division will be required 
for maintenance of most tissues. 
Therefore, the stem cells carrying 
mutations might be at the highest 
risk of becoming tumourigenic. 
Since blood-producing stem c:ells 
are particularly active, this may be 
the reason for a high incidence of 
leuka.~mias at a young age. 
A transient endogenous Stim-
ulation of cell division could 
induce autonomaus growth, not 
only by effident fixation of pri-
mary DNA Jesions, but also in 
combination with constitutively 
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controlled genes involved in cell 
proliferation. Thus other already 
affected but donnant genes 
involved in late steps of growth 
control might be activated. By a 
defective feedback mechanism25, 
autonomaus growth could be 
maintained via autocrine secretion 
of growth factors. This explains 
why tumour promoters can 
achieve their effect by growth 
Stimulation even when given a 
long time after the exposure to a 
mutagenic carcinogen. 
Cytotoxicity andgrowth 
The prolüerative stimulus fol-
lowing tissue darnage is a well 
regulated process" especially in 
cells that are responsible for repair 
processes, such as fibroblasts. 
These cells synthesize and release 
growth factors which can stimulate 
growth of tumour ceUs in vitro by a 
paracrine mechanism26• This in-
direct stimulation might also affect 
preneoplastic cells and could also 
function irl vivo. 
Clonal expRIIsion 
Another line of evidence sug· 
gests that tumour promoters can 
c:onvey a survival advantage to 
initiated cells. 
One hypothesis is deduced from 
the study of preneoplastic foci in 
liverunder the inßuence of tumour 
promoters such as phenobarbital 
or halogenated pestiddes like DDT 
or «·hexachlorocyclohexane. The 
postponed programmed cell death 
(apoptosis) in vivo27 and the arrest 
of processes involved in increasinj 
ploidy in hepatocyte cultures 
caused by these tumour promoters 
suggest that promotion is due to an 
altered or arrested differentiation 
process. Through this, a prolifera-
tion of stem cells is maintained 
with a few cells carrying the gen-
etic alteration necessary to become 
a tumour cell in the tissue; this 
Interpretation is supported by the 
obsf:rvation that among (originally 
tetraploid) hepatocytes of carcino-
gen-treated rats, a diploid (stem) cell 
popuJation &referentially emerges 
in tumours . 
A second mechanism was 
deduced from expeliments in 
which, after treatment of rats with 
a genotoxic hepatotoxin, cell popu-
lations arise in the liver that 
r_espond to growth stimuli (partial 
hepatectomy) but resist the 
cytostatic/cytotoxic activi~ of a 
second hepatocarcinogen . En-
zymes able to activate hepatocar-
cinogens seem to be expressed 
only at low Ievels in proliferating 
cells and therefore the already 
dividing c:ells have a further 
growth advantage. This mechan-
ism might, however, only play a 
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role in specific 
cases of chronic 
intoxication. 
Genotoxic 
activityof 
tumour 
promoters 
Evidenceexists 
that some tumour 
promoters [e.g. 
12-0-tetrade-
canoylphorbol-
13-acetate (TP A 
orPMA)]not 
only stimulate 
cell prolüeration 
but also induce 
chromosome 
aberrations31.32• 
Furthermore, 
recombinogenic 
eventshave 
been induced in 
embryosof 
pregnant mice 
bytumour 
promoters33, 
andpoint 
mutations are 
found in cells 
from epidermal papillomas and 
cardnomas that occur in mice after 
treatment with the phorbol esters 
TPA or mezerein alone34• It must 
therefore be postulated that at least 
some promotion steps result in 
genotoxic effects other than bind· 
ing to DNA and not detectable in 
presently available gene mutation 
tests. The uncertainty about the 
relevance of chromosome aberra-
tions and recombination in the 
promotion step is mainly caused 
by the Iack of mammalian test sys-
tems in which the whole spectrum 
of mutagenic events can be foJ .. 
lowed speclfically in the few initi-
ated cells of a tissue. 
Tumourprogression 
Since a dividing cell has an 
advantage over a resting cell with 
respect to transmitting its genetic 
infonnation to the progeny, aper-
manent selection process will 
favour those cells that have accu-
mulated the largest number of 
changes towards a malignant 
(infiltrative and metastatic) cancer 
cell phenotype. Cell death and 
regeneration are under close con-
trol of hormones, growth factors, 
intercellular communication and 
cell surface antigens; any interfer-
ence with these steps can Iead to 
an increased probability of rapid 
autonomaus tumour growth. 
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Tumour progression to maHg-
nancy is often associated with gross 
structural and numerical chromo-
somal abnormalities. However, it 
is believed that this massive 
destabilization of the genome 
without clonal origin is not the 
prerequisite for efficient cell pro-
liferation. 
Need formechanistic distinction 
The distinction between geno-
toxic and epigenetic activity· of 
carcinogeTts (Fig. 1) might sf'em 
rather theoretical for the cancer 
victim. However, we consider it 
essential to understand the bio-
logical processes underlying the 
process of carcinogenesis, since it 
is an important aspect when data 
obtained from animals are to be 
extrapolated to humans. For exam-
ple, when carcinogens are found to 
be transformed into chemically 
reactive metabolic intennediates 
interacting with DNA in some ani-
mal species, it will be impcrtant to 
find out whether the compound is 
metabolized in a similar way in 
humans. Additionally, the dose-
response relationship might be 
different for genotoxic cal'cinogens 
and those carcinogens that act only 
at high dose Ievels by inducing 
cytotoxicity and regenerating cell 
division, or those non-mutagenic 
carcinogen& that act at hormonal 
levels35 • 
An understanding of the 
mechanisms of carcinogenic activ-
ity might allow for the develop-
ment of a battery of short-term 
tests able to detect chemieals active 
in defined steps of carcinogenesis. 
This will facilitate better risk eval-
uation of chemical carcinogens. 
New tests to be devised should 
pennit a camparalive analysis of 
different types of mutations and 
the detection of chemieals that stim-
ulate cell proliferation and inter-
fere with cell differentiation. 
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Pharmacological approaches to 
the modulation of plasma 
cholesterol 
James Shepherd and Christopher J. Packard 
Several recent clinical trials have demonstrated that strategies that lower 
plasma cholesterollevels do indeed have a beneficial effect on events related to 
coronary heart disease. A major strategy to lower cholesterol Ievels is via. 
pharmacological intervention. James Shepherd and Christopher Packard 
evaluate the mechanisms and effectiveness of currently available classes of drug 
that act by lowering sterol absorption,lowering sterol synthesis, or interrupting 
the enterohepatic circulation. 
Health care services in industrial-
ized countries are becoming so 
bogged down in the treatment of 
established disease, that little is 
left to offer the population by way 
of preventive therapy. As a conse-
quence, chronic degenerative ill-
nesses are placing an ever increas-
ing burden on the resources of 
primary health care systems, des-
pite accumulating evidence that 
some of them may be improved by 
simple measures aimed at Iifestyle 
modification. 
Tames Shepherd is Professor and Christopher J. 
Packard is Principal Bioehemist in the Deparl-
ment o{ Biochemistry, Royal lnfirmary, 
Glasgow G4 OSF, UK. 
Coronary artery disease, for 
example, which is responsible for 
about a third of all deaths in 
industrial societies, appears to 
respond to interventions designed 
to alter population attitudes and 
habits. Several major risk factors-
hypercholesterolaemia, hyperten-
sion and cigarette smoking - con-
tribute to its development, and 
when treated produce significant 
advantage for the individual. The 
Lipid Research Cinks Coronar-t 
Primary Prevention Trial1, for 
example, offered convincing evi-
dence that lowering plasma chol-
esterol Ievels in asymptomatic 
hypercholesterolaemic men reduces 
their risk of having a myocardial 
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